Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback